WALTHAM, Mass.–(BUSINESS WIRE)–ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Daniel Char, JD, has been appointed Senior Vice President and Chief Legal Officer.
“We are pleased to welcome Daniel to ImmunoGen to lead our Legal team and join ImmunoGen’s Executive Committee. With his deep expertise advising on commercial, regulatory, compliance, and corporate governance matters, Daniel will play an important role as we increase the scale and complexity of the business as we build momentum with the launch of ELAHERE™ (mirvetuximab soravtansine-gynx) and advance the rest of our portfolio,” said Mark Enyedy, ImmunoGen’s President and Chief Executive Officer. “Daniel succeeds Joseph Kenny, who has served as our Acting General Counsel and Vice President since March 2020 and will remain with ImmunoGen serving in an Associate General Counsel capacity.”
Mr. Char joins ImmunoGen from Evelo Biosciences where he served as General Counsel and Secretary providing strategic counsel and operational support on a broad range of business and legal issues, including business development, commercialization, healthcare fraud, and intellectual property. Prior to joining Evelo, Mr. Char was Associate General Counsel and Assistant Secretary at Smith+Nephew, after having served as General Counsel and Secretary at Targanta Therapeutics, Senior Associate General Counsel at Idenix Pharmaceuticals, and Associate General Counsel at Biogen. Mr. Char holds a JD from Harvard Law School and a BA in Economics from Tufts University.
“I am thrilled to join ImmunoGen during this transformational period following the Company’s first product approval, and I look forward to working closely with the Executive Committee and Legal team to support ELAHERE’s successful launch,” said Mr. Char. “As a fully-integrated oncology company, ImmunoGen’s growth will be driven by both commercial execution and continued pipeline advancement, and I am excited to contribute as the organization evolves.”
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
ABOUT ELAHERE (MIRVETUXIMAB SORAVTANSINE-GYNX)
ELAHERE (mirvetuximab soravtansine-gynx) is a first-in-class ADC comprising a folate receptor alpha-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin inhibitor designed to kill the targeted cancer cells. Please see full Prescribing Information, including Boxed Warning for ELAHERE, here.
